Utah Medical Products, Inc. — Q1 2012 Form 10-Q
Business context and period: The filing covers the three months ended March 31, 2012. Utah Medical Products (UTMD) manufactures and markets specialty medical devices. Results include a full quarter of Femcare, acquired March 18, 2011, whereas Q1 2011 included only post-acquisition activity from March 18 onward. Dollar amounts below are in thousands, except per-share data.
Financial performance
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Net sales | $11,206 | $6,793 | +65% |
| Gross profit | $6,738 | $3,710 | +82% |
| Operating income | $4,115 | $2,158 | +91% |
| Income before taxes | $3,937 | $2,142 | +84% |
| Net income | $2,789 | $1,336 | +109% |
| Diluted EPS | $0.76 | $0.37 | +106% |
| Operating cash flow | $3,434 | $2,764 | +24% |
- Margins: Gross margin was 60.1% versus 54.6%; operating margin was 36.7% versus 31.8%; net margin was 24.9% versus 19.7%. Management attributed the gross-margin improvement primarily to Femcare’s higher-margin products. Higher volume and the absence of prior-year acquisition costs also supported operating margin.
- Cash and liquidity: Cash was $8,159 at quarter-end, up from $6,534 at year-end 2011. Working capital was $8,190, versus $7,385 at year-end. Receivables rose $1,331 from year-end; management said receivables and inventory remained within productivity targets.
- Debt: Total notes payable were $19,527, comprising $8,800 owed to Chase in the U.S., $10,230 to Chase in the U.K., and $497 to the Bank of Ireland. UTMD repaid $2,464 of notes in Q1. All loan covenants were reported in compliance; notes were scheduled to be repaid by April 2016.
- Cash flows and capital: Investing activities used $62, principally for $61 of property and equipment spending. Financing activities used $1,824, including debt repayment, partly offset by $585 from option exercises and a $55 tax benefit. Cash increased by $1,624. No cash dividends were paid during the quarter; a $878 dividend was accrued at quarter-end and paid afterward.
Comparisons and business drivers
- The year-over-year sales increase partly reflects the acquisition comparison: Femcare contributed $5,065 of Q1 2012 sales versus $491 in the post-acquisition portion of Q1 2011. On a pro forma basis, combined revenue was $11,206 versus $10,712 and net income was $2,789 versus $2,259.
- Femcare-related acquisition expenses of $259 were recorded in Q1 2011 and none in Q1 2012. Q1 2012 also included $635 of identifiable-intangible amortization, compared with $95 in Q1 2011.
- International sales increased 116% and represented 50% of sales, versus 38% a year earlier; domestic sales increased 34%. Gyn/ES sales rose 238%, while neonatal sales fell 6% and obstetrics sales fell 13%.
- UTMD reported that several large OEM/international distributor customers ordered substantially more than their prior quarterly averages. Such orders are uneven, and the company cautioned that quarterly revenue may be more volatile as OEM and distributor sales become a larger share of business.
Outlook, risks, and unusual items
- Management raised its 2012 diluted EPS estimate to $2.40–$2.45, from $2.35–$2.40 previously, implying 18%–20% growth over 2011. It expected Q2 2012 sales to be closer to $10 million after Q1’s unusually strong sales, and said CooperSurgical purchases were expected to be more than $1 million lower in Q2 than in Q1.
- Management said it remained on track to integrate Femcare, begin direct sales to end users in Ireland, introduce three gynecology products, maintain financial performance, and use cash generation for debt repayment, dividends, and potentially share repurchases.
- Key risks cited include medical-device regulation and approval delays, U.S. healthcare reform and the scheduled device excise tax, GPO and hospital purchasing pressures, product liability, reliance on overseas distributors, foreign-exchange movements, key-personnel dependence, and acquisition debt. UTMD reported no litigation believed likely to materially affect results, no warranty reserve based on its assessment of immaterial existing obligations, and no claims against Femcare’s $3.2 million seller escrow.
- Foreign-currency translation and other comprehensive items were significant: Q1 comprehensive income was $3,526, including $728 of foreign-currency translation adjustments. The company does not use separate hedging transactions.
- The filing states disclosure controls were effective, but identifies the evaluation date as March 31, 2011, an apparent inconsistency with the Q1 2012 report period.
Most important facts for investors to verify
- How much Q1 growth and the raised EPS outlook depend on Femcare, customer order timing, and nonrecurring acquisition-comparison effects.
- Whether Q2 sales and subsequent quarterly results reflect the anticipated normalization of large OEM and distributor orders.
- Debt repayment progress, covenant compliance, interest costs, and the company’s capacity to fund dividends and planned investment.
- The contribution of Femcare and international subsidiaries to profit, and the sustainability of reported margins and the lower effective tax rate.
- The disclosure-controls evaluation date inconsistency and the status of the scheduled medical-device excise tax and other regulatory risks.